Premium
Treatment outcome of young children with acute lymphoblastic leukaemia: achievements and directions implied from Shanghai Children's Medical Centre based SCMC ‐ ALL ‐2005 protocol
Author(s) -
Liang Yang,
Yang LinHai,
Jiang Hui,
Yuan XiaoJun,
Sun LiRong,
Wang NingLing,
Tang JingYan
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13288
Subject(s) - medicine , minimal residual disease , pediatrics , bone marrow , disease , hematology , risk stratification , clinical trial , complete remission , oncology , chemotherapy
Summary This multicenter study used the Shanghai Children's Medical Center ( SCMC )‐ ALL ‐2005 protocol for treatment of young patients (<2 years old) with acute lymphoblastic leukaemia ( ALL ), which was designed to improve treatment outcome in Chinese paediatric patients. These aims were pursued through risk‐directed stratification based on presenting clinical and genetic features, minimal residual disease ( MRD ) levels and treatment response. All the patients achieved completed remission with 5‐year event‐free survivals of 82·6 ± 9·7% (low risk), 52·6 ± 8·4% (intermediate risk), 28·6 ± 17·1% (high risk). Disease recurrence was detected in bone marrow, bone marrow plus testis, testis alone and central nervous system in 16 (24·2%), 1 (1·5%), 1 (1·5%) and 1 (1·5%) patients respectively. No deaths were reported during induction. The SCMC ‐ ALL ‐2005 trial for ALL patients <2 years old indicated high remission induction and low infection and treatment‐related mortality rates.